Abbott Laboratories (ABT) PB Ratio: 3.00
Is Abbott Laboratories’s P/B ratio high or low?
Abbott Laboratories's P/B ratio of 3.00 is 41% below its 5-year average of 5.09, near the low end of its 5-year range (2.77–7.35).
26.22% below its 12-month average of 4.07.
ABT PB Ratio Chart
ABT Average PB Ratio Chart
ABT Current vs Average PB Ratio Chart
ABT PB Ratio Metrics
PB RATIO
3.00
PB RATIO AVG TTM
4.07
PB RATIO AVG 3Y
4.66
PB RATIO AVG 5Y
5.09
PB RATIO AVG 10Y
4.67
PB RATIO AVG 15Y
3.93
PB RATIO AVG 20Y
3.48
CURRENT VS TTM AVG
-26.22%
CURRENT VS 3Y AVG
-35.58%
CURRENT VS 5Y AVG
-41.11%
CURRENT VS 10Y AVG
-35.74%
CURRENT VS 15Y AVG
-23.57%
CURRENT VS 20Y AVG
-13.70%
ABT Competitors' PB Ratio
| NAME | MARKET CAP | PB RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Abbott Laboratories (ABT) | $155.75B | 3.00 | 4.07 | 4.66 | 5.09 |
| Gilead Sciences, Inc. (GILD) | $156.35B | 6.48 | 7.47 | 6.02 | 5.35 |
| Pfizer Inc. (PFE) | $149.61B | 1.67 | 1.63 | 1.71 | 2.35 |
| Intuitive Surgical, Inc. (ISRG) | $144.79B | 8.48 | 10.30 | 10.61 | 9.88 |
| Thermo Fisher Scientific Inc. (TMO) | $176.21B | 3.41 | 3.75 | 4.21 | 4.73 |
| CVS Health Corporation (CVS) | $126.70B | 1.62 | 1.29 | 1.17 | 1.37 |
| Danaher Corporation (DHR) | $126.39B | 2.47 | 2.82 | 3.16 | 3.48 |
| Amgen Inc. (AMGN) | $188.37B | 19.99 | 21.33 | 23.63 | 31.88 |
| Bristol-Myers Squibb Company (BMY) | $116.13B | 5.79 | 5.81 | 5.35 | 4.99 |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.59B | 5.82 | 6.41 | 6.72 | 6.44 |
P/B vs. its own history
At 3.00, P/B is in its normal range, sitting higher than 50% of its 20-year history.
20-year low
1.33
median
3.00
20-year high
7.35
Book Value Analysis
P/B Ratio
3.00
Market Price / Book Value per Share
Abbott Laboratories PB Ratio Formula & Definition
PB Ratio = Market Cap / Total Shareholders' Equity
The price-to-book ratio compares market capitalization to book value (shareholders' equity). Lower values can indicate a cheaper valuation relative to net assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Abbott Laboratories PB Ratio FAQ
- What is the P/B ratio for Abbott Laboratories (ABT)?
- The P/B ratio for ABT stock is 3.00.
- Is Abbott Laboratories's P/B ratio high or low?
- Abbott Laboratories's P/B ratio of 3.00 is 41% below its 5-year average of 5.09, near the low end of its 5-year range (2.77–7.35).
- What is the TTM average P/B ratio for Abbott Laboratories (ABT)?
- The TTM average P/B ratio for ABT stock is 4.07.
- What is the 3Y average P/B ratio for Abbott Laboratories (ABT)?
- The 3Y average P/B ratio for ABT stock is 4.66.
- What is the 5Y average P/B ratio for Abbott Laboratories (ABT)?
- The 5Y average P/B ratio for ABT stock is 5.09.
- What is the 10Y average P/B ratio for Abbott Laboratories (ABT)?
- The 10Y average P/B ratio for ABT stock is 4.67.
- What is the 15Y average P/B ratio for Abbott Laboratories (ABT)?
- The 15Y average P/B ratio for ABT stock is 3.93.
- What is the 20Y average P/B ratio for Abbott Laboratories (ABT)?
- The 20Y average P/B ratio for ABT stock is 3.48.
Abbott Laboratories PB Ratio History
| DATE | PB RATIO |
|---|---|
| 2026-06-11 | 3.00 |
| 2026-06-10 | 2.99 |
| 2026-06-09 | 3.06 |
| 2026-06-08 | 3.04 |
| 2026-06-05 | 3.06 |
| 2026-06-04 | 3.05 |
| 2026-06-03 | 2.92 |
| 2026-06-02 | 2.92 |
| 2026-06-01 | 2.95 |
| 2026-05-29 | 2.87 |
| 2026-05-28 | 2.90 |
| 2026-05-27 | 2.88 |
| 2026-05-26 | 2.91 |
| 2026-05-22 | 2.93 |
| 2026-05-21 | 2.95 |
| 2026-05-20 | 2.97 |
| 2026-05-19 | 2.98 |
| 2026-05-18 | 2.95 |
| 2026-05-15 | 2.83 |
| 2026-05-14 | 2.85 |
| 2026-05-13 | 2.81 |
| 2026-05-12 | 2.83 |
| 2026-05-11 | 2.77 |
| 2026-05-08 | 2.83 |
| 2026-05-07 | 2.92 |
| 2026-05-06 | 2.90 |
| 2026-05-05 | 2.93 |
| 2026-05-04 | 2.94 |
| 2026-05-01 | 3.00 |
| 2026-04-30 | 3.05 |
| 2026-04-29 | 3.06 |
| 2026-04-28 | 3.15 |
| 2026-04-27 | 3.11 |
| 2026-04-24 | 3.05 |
| 2026-04-23 | 3.10 |
| 2026-04-22 | 3.07 |
| 2026-04-21 | 3.11 |
| 2026-04-20 | 3.22 |
| 2026-04-17 | 3.24 |
| 2026-04-16 | 3.20 |
| 2026-04-15 | 3.40 |
| 2026-04-14 | 3.39 |
| 2026-04-13 | 3.37 |
| 2026-04-10 | 3.36 |
| 2026-04-09 | 3.44 |
| 2026-04-08 | 3.47 |
| 2026-04-07 | 3.41 |
| 2026-04-06 | 3.43 |
| 2026-04-02 | 3.45 |
| 2026-04-01 | 3.43 |
| 2026-03-31 | 3.44 |
| 2026-03-30 | 3.41 |
| 2026-03-27 | 3.48 |
| 2026-03-26 | 3.50 |
| 2026-03-25 | 3.51 |
| 2026-03-24 | 3.49 |
| 2026-03-23 | 3.51 |
| 2026-03-20 | 3.53 |
| 2026-03-19 | 3.59 |
| 2026-03-18 | 3.64 |
| 2026-03-17 | 3.71 |
| 2026-03-16 | 3.68 |
| 2026-03-13 | 3.62 |
| 2026-03-12 | 3.62 |
| 2026-03-11 | 3.69 |
| 2026-03-10 | 3.70 |
| 2026-03-09 | 3.78 |
| 2026-03-06 | 3.67 |
| 2026-03-05 | 3.72 |
| 2026-03-04 | 3.79 |
| 2026-03-03 | 3.81 |
| 2026-03-02 | 3.82 |
| 2026-02-27 | 3.90 |
| 2026-02-26 | 3.90 |
| 2026-02-25 | 3.85 |
| 2026-02-24 | 3.84 |
| 2026-02-23 | 3.86 |
| 2026-02-20 | 3.76 |
| 2026-02-19 | 3.85 |
| 2026-02-18 | 3.89 |
| 2026-02-17 | 3.85 |
| 2026-02-13 | 3.87 |
| 2026-02-12 | 3.83 |
| 2026-02-11 | 3.90 |
| 2026-02-10 | 3.85 |
| 2026-02-09 | 3.81 |
| 2026-02-06 | 3.80 |
| 2026-02-05 | 3.74 |
| 2026-02-04 | 3.71 |
| 2026-02-03 | 3.74 |
| 2026-02-02 | 3.76 |
| 2026-01-30 | 3.75 |
| 2026-01-29 | 3.64 |
| 2026-01-28 | 3.64 |
| 2026-01-27 | 3.72 |
| 2026-01-26 | 3.73 |
| 2026-01-23 | 3.69 |
| 2026-01-22 | 3.73 |
| 2026-01-21 | 4.14 |
| 2026-01-20 | 4.16 |
| 2026-01-16 | 4.18 |
| 2026-01-15 | 4.24 |
| 2026-01-14 | 4.29 |
| 2026-01-13 | 4.27 |
| 2026-01-12 | 4.28 |
| 2026-01-09 | 4.32 |
| 2026-01-08 | 4.33 |
| 2026-01-07 | 4.36 |
| 2026-01-06 | 4.39 |
| 2026-01-05 | 4.34 |
| 2026-01-02 | 4.26 |
| 2025-12-31 | 4.30 |
| 2025-12-30 | 4.32 |
| 2025-12-29 | 4.28 |
| 2025-12-26 | 4.29 |
| 2025-12-24 | 4.28 |
| 2025-12-23 | 4.27 |
| 2025-12-22 | 4.30 |
| 2025-12-19 | 4.31 |
| 2025-12-18 | 4.29 |
| 2025-12-17 | 4.35 |
| 2025-12-16 | 4.35 |
| 2025-12-15 | 4.41 |
| 2025-12-12 | 4.31 |
| 2025-12-11 | 4.23 |
| 2025-12-10 | 4.21 |
| 2025-12-09 | 4.16 |
| 2025-12-08 | 4.19 |
| 2025-12-05 | 4.29 |
| 2025-12-04 | 4.30 |
| 2025-12-03 | 4.30 |
| 2025-12-02 | 4.34 |
| 2025-12-01 | 4.39 |
| 2025-11-28 | 4.42 |
| 2025-11-26 | 4.41 |
| 2025-11-25 | 4.40 |
| 2025-11-24 | 4.37 |
| 2025-11-21 | 4.40 |
| 2025-11-20 | 4.26 |
| 2025-11-19 | 4.33 |
| 2025-11-18 | 4.46 |
| 2025-11-17 | 4.46 |
| 2025-11-14 | 4.48 |
| 2025-11-13 | 4.44 |
| 2025-11-12 | 4.42 |
| 2025-11-11 | 4.36 |
| 2025-11-10 | 4.32 |
| 2025-11-07 | 4.34 |
| 2025-11-06 | 4.29 |
| 2025-11-05 | 4.27 |
| 2025-11-04 | 4.32 |
| 2025-11-03 | 4.25 |
| 2025-10-31 | 4.24 |
| 2025-10-30 | 4.28 |
| 2025-10-29 | 4.27 |
| 2025-10-28 | 4.38 |
| 2025-10-27 | 4.40 |
| 2025-10-24 | 4.39 |
| 2025-10-23 | 4.37 |
| 2025-10-22 | 4.43 |
| 2025-10-21 | 4.42 |
| 2025-10-20 | 4.48 |
| 2025-10-17 | 4.45 |
| 2025-10-16 | 4.42 |
| 2025-10-15 | 4.48 |
| 2025-10-14 | 4.61 |
| 2025-10-13 | 4.55 |
| 2025-10-10 | 4.59 |
| 2025-10-09 | 4.62 |
| 2025-10-08 | 4.65 |
| 2025-10-07 | 4.61 |
| 2025-10-06 | 4.63 |
| 2025-10-03 | 4.66 |
| 2025-10-02 | 4.61 |
| 2025-10-01 | 4.62 |
| 2025-09-30 | 4.64 |
| 2025-09-29 | 4.61 |
| 2025-09-26 | 4.62 |
| 2025-09-25 | 4.62 |
| 2025-09-24 | 4.64 |
| 2025-09-23 | 4.71 |
| 2025-09-22 | 4.73 |
| 2025-09-19 | 4.71 |
| 2025-09-18 | 4.66 |
| 2025-09-17 | 4.65 |
| 2025-09-16 | 4.60 |
| 2025-09-15 | 4.55 |
| 2025-09-12 | 4.63 |
| 2025-09-11 | 4.59 |
| 2025-09-10 | 4.48 |
| 2025-09-09 | 4.57 |
| 2025-09-08 | 4.58 |
| 2025-09-05 | 4.60 |
| 2025-09-04 | 4.60 |
| 2025-09-03 | 4.58 |
| 2025-09-02 | 4.55 |
| 2025-08-29 | 4.59 |
| 2025-08-28 | 4.55 |
| 2025-08-27 | 4.55 |
| 2025-08-26 | 4.56 |
| 2025-08-25 | 4.57 |
| 2025-08-22 | 4.59 |
| 2025-08-21 | 4.57 |
| 2025-08-20 | 4.59 |
| 2025-08-19 | 4.55 |
| 2025-08-18 | 4.51 |
| 2025-08-15 | 4.56 |
| 2025-08-14 | 4.48 |
| 2025-08-13 | 4.48 |
| 2025-08-12 | 4.54 |
| 2025-08-11 | 4.55 |
| 2025-08-08 | 4.65 |
| 2025-08-07 | 4.57 |
| 2025-08-06 | 4.53 |
| 2025-08-05 | 4.53 |
| 2025-08-04 | 4.50 |
| 2025-08-01 | 4.41 |
| 2025-07-31 | 4.37 |
| 2025-07-30 | 4.45 |
| 2025-07-29 | 4.58 |
| 2025-07-28 | 4.52 |
| 2025-07-25 | 4.53 |
| 2025-07-24 | 4.50 |
| 2025-07-23 | 4.50 |
| 2025-07-22 | 4.50 |
| 2025-07-21 | 4.45 |
| 2025-07-18 | 4.43 |
| 2025-07-17 | 4.31 |
| 2025-07-16 | 4.72 |
| 2025-07-15 | 4.71 |
| 2025-07-14 | 4.73 |
| 2025-07-11 | 4.73 |
| 2025-07-10 | 4.78 |
| 2025-07-09 | 4.77 |
| 2025-07-08 | 4.77 |
| 2025-07-07 | 4.79 |
| 2025-07-03 | 4.81 |
| 2025-07-02 | 4.80 |
| 2025-07-01 | 4.88 |
| 2025-06-30 | 4.87 |
| 2025-06-27 | 4.81 |
| 2025-06-26 | 4.78 |
| 2025-06-25 | 4.92 |
| 2025-06-24 | 4.94 |
| 2025-06-23 | 4.77 |
| 2025-06-20 | 4.76 |
| 2025-06-18 | 4.74 |
| 2025-06-17 | 4.74 |
| 2025-06-16 | 4.80 |
| 2025-06-13 | 4.85 |
| 2025-06-12 | 4.88 |
| 2025-06-11 | 4.84 |
| 2025-06-10 | 4.80 |
| 2025-06-09 | 4.78 |
| 2025-06-06 | 4.78 |
| 2025-06-05 | 4.79 |
| 2025-06-04 | 4.76 |
| 2025-06-03 | 4.79 |
| 2025-06-02 | 4.78 |
| 2025-05-30 | 4.78 |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert Ford